Industry News
-
Atsena Reports Durable AAV Gene Therapy Data in XLRS and LCA1 at ARVO 2026
May 07 2026 -
Opus Genetics Completes Enrollment in Cohort 1 of OPGx-BEST1 Gene Therapy Study for BEST Disease
May 07 2026 -
REYON and Elligene Report 52-Week AAV Gene Therapy NG101 Data in Wet AMD
May 07 2026 -
Apertura Gene Therapy and TSC Alliance Collaborate to Advance AAV Gene Therapy Programs for Tuberous Sclerosis Complex
May 06 2026 -
Valerio Therapeutics Launches InVimmune to Advance In Vivo Cell Therapy
May 05 2026 -
NINDS Awards $3.2 Million Grant to Advance AAV9 Gene Therapy Development for UBA5 Disorder
May 05 2026 -
Sangrail Biologics Launches with Lead AAV9 Gene Therapy Program for MPS IIIB
May 05 2026 -
Systemic AAV Gene Therapy Shows Clinical Response in Late-Stage Lysosomal Storage Disease Model
May 05 2026 -
Opus Genetics’ OPGx-LCA5 Gene Therapy Accepted into FDA RDEP Program
May 05 2026